The Zhitong Finance App learned that on Monday, Moderna (MRNA.US) rose more than 8% at the beginning of the session. As of press release, the increase had narrowed beyond 5% to 229.69 US dollars. The stock price was close to an all-time high. According to the news, on October 17, Moderna and MSD collaborated to present the melanoma phase III study on individualized cancer treatment IntiSmeran Autogene combined with Keytruda. Reports indicate that this candidate treatment has made positive progress.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.